ChromaCode, Inc., a Carlsbad, Calif.-based molecular diagnostics company, raised $12m in Series B funding.
The round was led by New Enterprise Associates (NEA) with participation from existing investors Domain Associates and Okapi Ventures. In conjunction with the funding, Alex Dickinson, Ph.D., was appointed as Executive Chairman. He joins the company from Illumina, where he was senior vice president of strategic initiatives and had prior responsibility for cloud genomics and PCR initiatives. NEA Partner Justin Klein, M.D. will be joining the Board of Directors.
The company intends to use the funds to accelerate the development and establish the commercial infrastructure for its technology.
Led by CEO Greg Gosch, ChromaCode is a molecular diagnostics company with a bioinformatics focus. Its software and assay technology, High-Definition Polymerase Chain Reaction technology (HDPCR™), leverages existing real-time PCR instruments and uses digital signal processing to improve molecular analysis.